» Articles » PMID: 9658402

FRA-1 Expression Level Modulates Regulation of Activator Protein-1 Activity by Estradiol in Breast Cancer Cells

Overview
Journal Mol Endocrinol
Date 1998 Jul 11
PMID 9658402
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

We compared the effect of estradiol on activator protein-1 (AP-1) activity in estrogen receptor positive (ER alpha+) and estrogen receptor negative (ER alpha-) human breast cancer cell lines transiently transfected with the AP-1-responsive reporter plasmid AP-1-TK-CAT and an ER alpha expression vector. While estradiol increased AP-1 activity in the ER alpha+ cell lines MCF7, ZR75.1, and T47D, it decreased (MDA-MB231 and BT20 cells) or had no significant effect (MDA-MB435 cells) on AP-1-mediated transcription in ER alpha- cells. Estradiol also inhibited AP-1 activity in ER alpha-MDA-MB231 cells stably transfected with ER alpha and in which ER alpha levels are close to those found in MCF7. Use of ER alpha mutant expression vectors demonstrated that the DNA-binding domain of ER alpha was needed for stimulation or inhibition of AP-1 activity by estradiol but suggested that ER alpha binding to estrogen-responsive elements was not required for these effects. Changes in regulation paralleled quantitative and qualitative changes in protein binding to AP-1 sites, as demonstrated by gel shift assay: protein binding was greater and DNA/protein complexes migrated faster for ER alpha--than for ER alpha+ cells. In fact, by Northern blot, a high level of Fra-1 mRNA was found in BT20 and MDA-MB231 cells as compared with ER alpha+ cells, and MDA-MB435 cells showed an intermediary level of expression. The differential expression of Fra-1 in MCF7 and MDA-MB231 cells was confirmed at the protein level by supershift experiments. In addition, overexpression of Fra-1 in MCF7 cells decreased the positive effect of estradiol while inhibition of Fra-1 expression in MDA-MB231 cells, by transient transfection of the Fra-1 antisense expression vector, abolished the negative effect of the hormone. In conclusion, we demonstrated that ER alpha- breast cancer cell lines differ from ER+ cells by a high level of AP-1 DNA-binding activity due, at least in part, to high Fra-1 constitutive expression. High Fra-1 concentration is crucial for the negative regulation of AP-1 activity by estradiol and thus may take part in estradiol-induced inhibition of cell proliferation in ER alpha- breast cancer cells transfected with ER alpha expression construct.

Citing Articles

Development of double strand RNA mPEI nanoparticles and application in treating invasive breast cancer.

Liu R, Mu L, Bai J, Du Y, Xie Y, Lu W RSC Adv. 2022; 9(23):13186-13200.

PMID: 35520771 PMC: 9063785. DOI: 10.1039/c9ra01889a.


Estrogen Reverses HDAC Inhibitor-Mediated Repression of and Class-Switching in Antibody and Autoantibody Responses by Downregulation of miR-26a.

Casali P, Shen T, Xu Y, Qiu Z, Chupp D, Im J Front Immunol. 2020; 11:491.

PMID: 32265934 PMC: 7105609. DOI: 10.3389/fimmu.2020.00491.


Forskolin and Phorbol 12-myristate 13-acetate modulates the expression pattern of AP-1 factors and cell cycle regulators in estrogen-responsive MCF-7 cells.

Babu R, Kumar M, Patil R, Kiran Kumar K, Devaraju K, Ramesh G Genes Dis. 2019; 6(2):159-166.

PMID: 31194000 PMC: 6545452. DOI: 10.1016/j.gendis.2018.12.001.


Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties.

Oliveira-Ferrer L, Kurschner M, Labitzky V, Wicklein D, Muller V, Luers G J Cancer Res Clin Oncol. 2015; 141(10):1715-26.

PMID: 25666264 DOI: 10.1007/s00432-015-1925-2.


Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Bhola N, Jansen V, Bafna S, Giltnane J, Balko J, Estrada M Cancer Res. 2014; 75(2):405-14.

PMID: 25480943 PMC: 4297507. DOI: 10.1158/0008-5472.CAN-14-2475.